Stockscreener 앱 받기
16.12
0.19%
0.03
시간 외 거래:
16.10
-0.02
-0.12%
전일 마감가:
$16.09
열려 있는:
$15.78
하루 거래량:
2.62M
Relative Volume:
1.00
시가총액:
$12.00B
수익:
$220.00K
순이익/손실:
$-921.61M
주가수익비율:
-12.98
EPS:
-1.2418
순현금흐름:
$-274.60M
1주 성능:
+2.81%
1개월 성능:
-2.24%
6개월 성능:
-38.47%
1년 성능:
-14.44%
1일 변동 폭
$15.50
$16.80
1주일 범위
$15.39
$16.80
52주 변동 폭
$13.83
$36.91
Summit Therapeutics Inc Stock (SMMT) Company Profile
명칭
Summit Therapeutics Inc
전화
305-203-2034
주소
601 BRICKELL KEY DRIVE, MIAMI
Compare SMMT vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SMMT
Summit Therapeutics Inc
|
16.12 | 11.98B | 220.00K | -921.61M | -274.60M | -1.2418 |
|
VRTX
Vertex Pharmaceuticals Inc
|
487.43 | 122.19B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
772.19 | 83.21B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
840.28 | 51.13B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
332.85 | 43.68B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
369.00 | 41.01B | 4.98B | 69.60M | 525.67M | 0.5198 |
Summit Therapeutics Inc Stock (SMMT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-17 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2025-11-18 | 개시 | Wolfe Research | Peer Perform |
| 2025-09-17 | 개시 | Barclays | Underweight |
| 2025-09-04 | 개시 | Guggenheim | Buy |
| 2025-08-19 | 개시 | Piper Sandler | Neutral |
| 2025-07-01 | 개시 | UBS | Buy |
| 2025-06-11 | 개시 | Leerink Partners | Underperform |
| 2025-03-26 | 업그레이드 | Citigroup | Neutral → Buy |
| 2025-03-21 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-03-12 | 개시 | Evercore ISI | Outperform |
| 2025-02-28 | 개시 | Goldman | Buy |
| 2025-01-08 | 개시 | Truist | Buy |
| 2024-12-11 | 개시 | Wells Fargo | Overweight |
| 2024-12-06 | 개시 | Jefferies | Buy |
| 2024-11-04 | 개시 | JMP Securities | Mkt Outperform |
| 2024-09-27 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2024-08-12 | 개시 | H.C. Wainwright | Buy |
| 2024-05-07 | 개시 | Citigroup | Buy |
| 2024-03-26 | 개시 | Stifel | Buy |
| 2018-06-28 | 다운그레이드 | Janney | Buy → Neutral |
| 2018-05-02 | 개시 | Janney | Buy |
| 2018-04-12 | 재확인 | Needham | Buy |
| 2018-02-13 | 개시 | BTIG Research | Buy |
| 2018-01-04 | 개시 | SunTrust | Buy |
| 2017-12-01 | 재개 | H.C. Wainwright | Buy |
| 2016-11-16 | 재확인 | RBC Capital Mkts | Outperform |
| 2016-10-05 | 재확인 | Needham | Buy |
| 2016-09-16 | 개시 | H.C. Wainwright | Buy |
| 2015-03-30 | 개시 | Needham | Buy |
| 2015-03-30 | 개시 | Oppenheimer | Outperform |
모두보기
Summit Therapeutics Inc 주식(SMMT)의 최신 뉴스
Summit Therapeutics Inc (SMMT) Q4 2025 Earnings Call Highlights: - GuruFocus
Earnings Call Summary | Summit Therapeutics(SMMT.US) Q4 2025 Earnings Conference - 富途牛牛
SMMT Incurs Wider-Than-Expected Q4 Loss, Pipeline Progress in Focus - TradingView
Assessing Summit Therapeutics (SMMT) Valuation After Recent Share Price Swings - simplywall.st
Summit Therapeutics Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
SMMT: Analyst Lowers Price Target to $30, Maintains Buy Rating | SMMT Stock News - GuruFocus
Summit Therapeutics (SMMT) Q4 Earnings Miss Expectations - GuruFocus
Summit Therapeutics (SMMT) Set for Potential Upside Ahead of Key Data Release - GuruFocus
Summit Therapeutics (SMMT) Highlights Progress in Cancer Drug De - GuruFocus
Summit Therapeutics (SMMT) Is Up 7.6% After Steep Losses And New US$102 Million Shelf RegistrationHas The Bull Case Changed? - Yahoo Finance
Decoding Summit Therapeutics Inc (SMMT): A Strategic SWOT Insigh - GuruFocus
Earnings call transcript: Summit Therapeutics Q4 2025 reports significant EPS miss - Investing.com Nigeria
Summit Therapeutics Q4 Earnings Call Highlights - Yahoo Finance
Summit Therapeutics (SMMT) Updates on HARMONi-3 Trial Progress - GuruFocus
Summit Therapeutics falls on earnings miss despite progress By Investing.com - Investing.com South Africa
Summit Therapeutics falls on earnings miss despite progress - Investing.com
Summit Therapeutics Reports 2025 Results, Advances Ivonescimab Programs - TipRanks
Summit Therapeutics Q4 Net Loss Widens, Yearly Cash Equivalents Rise - marketscreener.com
Summit Therapeutics Inc. SEC 10-K Report - TradingView
Summit Therapeutics: Q4 Earnings Insights - Benzinga
Summit Therapeutics (NASDAQ: SMMT) posts 2025 loss but ends year with $713M cash - Stock Titan
Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2025 - Yahoo Finance
Summit Therapeutics (SMMT) Shows Elevated Options Activity Ahead of Earnings - GuruFocus
Highs Report: Can Summit Therapeutics Inc stock outperform in a bear marketJuly 2025 Snapshot & Fast Moving Trade Plans - baoquankhu1.vn
Summit Therapeutics Set to Announce Q4 Earnings on February 23 - Intellectia AI
Summit Therapeutics (SMMT) Set to Release Q4 Earnings - GuruFocus
Preview: Summit Therapeutics's Earnings - Benzinga
Skandinaviska Enskilda Banken AB publ Has $6.99 Million Holdings in Summit Therapeutics PLC $SMMT - MarketBeat
Precision Trading with Summit Therapeutics Inc. (SMMT) Risk Zones - Stock Traders Daily
Summit Therapeutics to Host Fourth Quarter and Full Year 2025 Financial Results & Operational Progress Call on February 23, 2026 - BioSpace
Market Rankings: Will Summit Therapeutics Inc outperform the market in YEAR2025 Pullback Review & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
Summit Therapeutics (SMMT) Grabs Investor Attention After Major FDA Breakthrough - Yahoo Finance
Summit Therapeutics (SMMT) to Release Earnings on Monday - MarketBeat
Is Summit Therapeutics Inc. stock near bottom after decline2025 Major Catalysts & Free Fast Entry Momentum Trade Alerts - mfd.ru
Can Summit Therapeutics Inc. stock outperform in a bear marketWeekly Profit Summary & Weekly Setup with High ROI Potential - mfd.ru
Analysis Recap: How is STSSW managing supply chain issuesJuly 2025 Review & Daily Stock Momentum Reports - baoquankhu1.vn
Is Summit Therapeutics Inc. (SMMT) One of the Most Oversold NASDAQ Stocks to Invest In? - Bitget
FDA accepts Summit Therapeutics’ (SMMT) BLA for ivonescimab in NSCLC with November 14 PDUFA date following positive phase III data - MSN
Summit Therapeutics Insiders Placed Bullish Bets Worth US$275.0m - 富途牛牛
Summit Therapeutics (SMMT) Is Up 6.5% After FDA Accepts Ivonescimab BLA With 2026 PDUFA Date - simplywall.st
Is Summit Therapeutics Inc. stock a good pick for beginnersMarket Activity Report & Risk Controlled Daily Plans - baoquankhu1.vn
Summit Therapeutics Enters FDA Review As Ivonescimab Trials Broaden Potential - Sahm
First Week of February 20th Options Trading For Summit Therapeutics (SMMT) - Nasdaq
Summit Therapeutics PLC (NASDAQ:SMMT) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Is Summit Therapeutics (SMMT) Pricing Reflecting Its Recent Share Price Pullback Accurately - Yahoo Finance
Technical Reactions to SMMT Trends in Macro Strategies - Stock Traders Daily
Summit Therapeutics (NASDAQ:SMMT) Rating Lowered to Strong Sell at Zacks Research - MarketBeat
FDA Accepts Summit Therapeutics’ (SMMT) BLA For Ivonescimab In NSCLC With November 14 PDUFA Date Following Positive Phase III Data - Yahoo Finance
Summit Therapeutics stock hits 52-week low at 14.01 USD By Investing.com - Investing.com Canada
FDA Accepts Summit Therapeutics' (SMMT) BLA For Ivonescimab In NSCLC With November 14 PDUFA Date Following Positive Phase III Data - Finviz
Merger Talk: Is Summit Therapeutics Inc impacted by rising rates2025 Buyback Activity & Fast Moving Stock Trade Plans - baoquankhu1.vn
Summit Therapeutics Inc (SMMT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.20%
0.26%
자본화:
|
볼륨(24시간):